Bucladesine
From Wikipedia, the free encyclopedia
 |
|
|
Bucladesine
|
|
| Systematic (IUPAC) name | |
| sodium [(1R,2R,4R,5R)-2-[6-(butanoylamino)purin- 9-yl]-7-oxido-7-oxo-3,6,8-trioxa-7λ5- phosphabicyclo[3.3.0]oct-4-yl]methyl butanoate |
|
| Identifiers | |
| CAS number | |
| ATC code | C01 |
| PubChem | |
| Chemical data | |
| Formula | C18H23N5NaO8P |
| Mol. mass | 491.368 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Bucladesine is a phosphodiesterase inhibitor.
|
|
|
|---|---|
| PDE1 | Vinpocetine |
| PDE2 | EHNA |
| PDE3 | Amrinone, Bucladesine, Enoximone, Milrinone |
| PDE4 | Mesembrine, Rolipram |
| PDE5 | Sildenafil, Tadalafil, Vardenafil |
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
